Research Reports

Key takeaways

Clare Fisher elected to Board of Directors, bringing extensive pharma business development experience from BeOne Medicines, Kaleido, Shire, and others.

All Board proposals approved by wide majority, including annual review, IFRS financial statements, and compensation report.

Net loss for 2025 of CHF 57,853,768 carried forward, increasing loss position to CHF 257,293,925.

Steven H. Holtzman retired after 12 years; all other Board members re-elected for one-year term.

Bill Burns re-elected Chairman; committee changes include Agnete Fredriksen replacing Holtzman.

KPMG re-elected auditors for 2026; binding compensation motions approved.

Full analysis

The 2026 AGM outcomes reflect strong shareholder support for Molecular Partners' governance, with unanimous approval of all board proposals signaling alignment on strategy amid ongoing clinical development. Clare Fisher's election adds significant expertise in business development, M&A, and partnerships from her roles at BeOne Medicines (SVP Global BD & M&A), Kaleido (CBO), Shire/Takeda (Group VP Transactions), and others, positioned to enhance the company's pipeline expansion and collaborations. Bill Burns' re-election as Chairman ensures leadership continuity. Financially, confirmation of 2025 results with a CHF 57.9 million net loss carryforward (totaling CHF 257.3 million) provides closure without distribution, typical for a clinical-stage biotech. Board discharge grants legal protection for 2025 performance, while compensation approvals set frameworks for incentives. Auditor and proxy re-elections maintain operational stability.

MOLN · Molecular Partners AG

Summary

Key takeaways

Full analysis